CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
肿瘤中的 CD39 (ENTPD1)：潜在治疗靶点与预后生物标志物
英文原题：CD39 (ENTPD1) in tumors: a potential therapeutic target and prognostic biomarker.
查看英文原题
CD39 (ENTPD1) in tumors: a potential therapeutic target and prognostic biomarker.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
外核苷三磷酸二磷酸水解酶CD39（ENTPD1）调节具有免疫激活作用的细胞外ATP与免疫抑制性腺苷之间的动态平衡。CD39会削弱免疫细胞发挥抗癌免疫的能力，并在肿瘤微环境中的免疫逃逸过程中发挥重要作用。此外，研究人员已在癌症患者中评估CD39与预后、免疫治疗（如PD-1阻断）疗效及复发预测之间的关系。本文综述CD39在肿瘤免疫学中的作用，汇总靶向CD39治疗肿瘤的临床前证据，并重点讨论CD39作为评估肿瘤预后及免疫检查点抑制剂应答生物标志物的潜力。
展开英文摘要原文
As a regulator of the dynamic balance between immune-activated extracellular ATP and immunosuppressive adenosine, CD39 ectonucleotidase impairs the ability of immune cells to exert anticancer immunity and plays an important role in the immune escape of tumor cells within the tumor microenvironment.
In addition, CD39 has been studied in cancer patients to evaluate the prognosis, the efficacy of immunotherapy (e. g. , PD-1 blockade) and the prediction of recurrence. This article reviews the importance of CD39 in tumor immunology, summarizes the preclinical evidence on targeting CD39 to treat tumors and focuses on the potential of CD39 as a biomarker to evaluate the prognosis and the response to immune checkpoint inhibitors in tumors.
论文信息
- 作者
- Li C、Zhang L、Jin Q、Jiang H、Wu C
- 单位
- Department of Hematology, Lanzhou University Second Hospital, Lanzhou, 730000, China.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Biomarkers in medicine2023 Jun
- 原文标识
- PubMed 37713234 · DOI 10.2217/bmm-2023-0202